DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B Share Price

Certificat

DE000ME8HBX7

Real-time Bid/Ask 17:01:00 03/07/2024 BST
111.05 EUR / 111.07 EUR -1.92% Intraday chart for DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B
Current month-0.52%
1 month+3.56%
Date Price Change
03/07/24 112.6 -0.60%
02/07/24 113.2 -0.88%
01/07/24 114.2 +0.36%
28/06/24 113.8 -0.03%
27/06/24 113.8 -0.18%

Delayed Quote Börse Stuttgart

Last update July 03, 2024 at 11:52 am

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME8HBX
ISINDE000ME8HBX7
Date issued 09/02/2024
Cap 130 $
Last trading day 20/12/2024
Maturity 20/12/2024 (170 Days)
Parity 1 : 1
Emission price 102.8
Emission volume N/A
Payment day 31/12/2024
Bonus-
Settlement règlement en espèces
Currency EUR

Technical Indicators

Discount (ask) 13.11 %
Sideways yield 8.405 %
Sideways yield pa 18.05 %
Outperformance point 149.6 $
Break even 119.92 €
Highest since issue 114.6
Lowest since issue 100.3
Spread 0.04
Spread %0.04%
Distance Cap 7.54 $
Distance Cap %+5.48%
Max. earning 9.333
Max. earning % 8.405 %

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5 DKK
Average target price
952.2 DKK
Spread / Average Target
-4.16%
Consensus